A patient is using topical and patch estrogen replacement therapy, reports no progesterone use, and has an intrauterine device (IUD) of unspecified type (hormonal or copper); why might she not be taking progesterone?

Why This Patient May Not Be Taking Progesterone

If this patient has a levonorgestrel-releasing IUD (hormonal IUD), she does not need additional systemic progesterone because the IUD itself provides adequate endometrial protection against estrogen-induced hyperplasia through local progestin delivery. 1

Clinical Reasoning Algorithm

Step 1: Determine IUD Type

The critical first step is to identify whether the patient has a hormonal (levonorgestrel) IUD or copper IUD, as this fundamentally changes the clinical picture:

• If Levonorgestrel IUD (Mirena, Skyla, Liletta, Kyleena):

  • The IUD releases 14-20 mcg levonorgestrel daily directly into the uterine cavity 2
  • This provides adequate endometrial protection when combined with systemic estrogen therapy 3, 4
  • No additional systemic progesterone is needed 5, 6, 7
  • This is approved in over 100 countries for endometrial protection with estrogen therapy for up to 5 years 8

• If Copper IUD (Paragard):

  • Provides no progestin effect 2
  • Patient requires systemic progesterone to prevent endometrial hyperplasia 1
  • This would represent a significant gap in care requiring immediate correction

Step 2: Assess Endometrial Protection Status

For women with an intact uterus taking systemic estrogen, endometrial protection is mandatory to prevent endometrial hyperplasia and cancer. 1

The FDA-approved dosing for oral progesterone with estrogen therapy is:

• 200 mg daily for 12 consecutive days per 28-day cycle (sequential regimen) 1
• Taken at bedtime due to sedation effects 1

Step 3: Verify Adequate Protection with Levonorgestrel IUD

If the patient has a levonorgestrel IUD, the evidence supports its use for endometrial protection:

• Multiple studies demonstrate safety and efficacy of combining transdermal/topical estrogen with levonorgestrel IUD 5, 6, 9
• The local progestin effect is sufficient to oppose estrogen's proliferative effects on the endometrium 7, 10
• 80% of women achieve amenorrhea by 12 months with this regimen 5
• This combination is considered "one of the most effective, safest and best accepted" hormone therapy regimens 9

Common Clinical Scenarios

Most Likely Scenario: Levonorgestrel IUD

The patient is likely using a hormonal IUD that provides local endometrial protection, making systemic progesterone unnecessary. This is an appropriate and evidence-based hormone therapy regimen. 3, 5, 9

Alternative Scenario: Copper IUD

If she has a copper IUD, this represents a critical gap in care. Women with an intact uterus taking unopposed estrogen face significantly increased risk of endometrial hyperplasia and cancer. 1

Critical Pitfalls to Avoid

1. Never assume the IUD type - Always verify whether it's hormonal or copper
2. Do not prescribe additional systemic progesterone if she has a levonorgestrel IUD - this provides no additional benefit and adds unnecessary medication burden
3. Do not delay progesterone initiation if she has a copper IUD - unopposed estrogen exposure is dangerous
4. Remember the levonorgestrel IUD is off-label in the US for endometrial protection (though approved in 100+ other countries), so documentation of informed consent is prudent 8

Immediate Action Required

Contact the patient to clarify IUD type immediately. If copper IUD is confirmed, initiate progesterone 200 mg daily for 12 days per month cycle without delay. 1 If levonorgestrel IUD is confirmed, document that adequate endometrial protection is in place and no additional progesterone is needed.

The levonorgestrel IUD provides effective endometrial protection for up to 5 years when combined with estrogen therapy, though some data suggest efficacy may extend to 8 years for contraceptive purposes. 8, 11